Dossier assessment
Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with metastatic colorectal cancer with a BRAF V600E mutation who have received prior systemic therapy
Added benefit not proven due to lack of suitable study data
Project details
- Project no.
- A20-56
- Commission
- Commission awarded on 30.06.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed